Codis Set to Acquire Catalent’s Nottingham Facility, Leading the Way in European Spray Dry Solutions

Codis Strengthens Its Spray Dry Capabilities

Codis, a prominent player in contract development and manufacturing, has taken a significant step in the pharmaceutical landscape by announcing its intention to acquire Catalent Pharma Solutions' facility located in Nottingham, UK. This strategic acquisition is set to transform Codis into a leading provider of comprehensive end-to-end spray dry solutions across Europe, establishing a notable presence within the market.

The deal, expected to close in the third quarter of this year following customary approvals, aims to enhance Codis' existing capabilities. The Nottingham facility has garnered over two decades of experience in oral solid dose (OSD) development and small-scale manufacturing, making it a valuable asset for the company. With the addition of this site, Codis will merge clinical supply with an integrated production pipeline, allowing for a smoother transition from development to commercial-scale manufacturing.

Advancements in Particle Engineering

One of the essential aspects of this acquisition is the opportunity for Codis to advance its expertise in particle engineering. Codis has strategically invested in its commercial-scale facility in Haverhill, UK, which is currently undergoing an expansion to incorporate a GEA Pharma-SD® type PSD-4 commercial spray dryer, expected to be operational by 2027. Together with the Nottingham site, Codis will now possess a unique combined capacity that fosters innovation and accelerates the development of new pharmaceutical formulations.

Nicolas Fortin, the CEO of Codis, stated, "This strategic acquisition will further establish Codis as a leading European provider of comprehensive spray dry solutions." He emphasized the unique advantages associated with the close proximity of the Nottingham and Haverhill facilities, noting how it streamlines access to top scientific expertise while maintaining robust manufacturing capabilities within one cohesive organization.

The integration of formulation development and GMP manufacturing under one roof is expected to mitigate the common risks associated with transitioning from laboratory-scale activities to commercial production. As Fortin explained, numerous small-molecule drug candidates face challenges due to poor solubility, where spray-dried dispersions emerge as a vital method to enhance bioavailability. This offering will help unlock a broader spectrum of pharmaceutical potentials, bridging theoretical approaches with practical manufacturing.

The Impact on European Pharmaceutical Landscape

This acquisition holds significant implications for the European pharmaceutical sector. As Codis continues to grow and innovate, it positions itself as a critical player in meeting the global demands for high-quality drug development and manufacturing solutions. The additional capabilities of the Nottingham facility will allow Codis to serve not only existing clients more effectively but also attract new partnerships in pharmaceutical and consumer health markets.

Moreover, Codis's ongoing investment in expanding its facilities underlines a commitment to enhancing customer confidence and satisfaction in their production processes. The company's ability to provide a highly integrated approach across the development continuum is expected to appeal to many pharmaceutical companies looking for efficient, low-risk pathways for their product development.

Conclusion

In summary, Codis's acquisition of Catalent's Nottingham facility represents a forward-thinking maneuver designed to consolidate its position in the pharmaceutical manufacturing arena. With a focus on innovation and excellence in spray dry solutions, Codis embarks on a new chapter, promising to deliver enhanced performance and solutions that meet the evolving needs of the industry and its stakeholders. As the world of pharmaceuticals continues to evolve, Codis's integral role in shaping the landscape will undoubtedly be one to watch.

To learn more about Codis and their innovative solutions, visit www.codis.com.